As of close of business last night, Amylyx Pharmaceuticals Inc’s stock clocked out at $2.74, down -4.53% from its previous closing price of $2.87. In other words, the price has decreased by -$0.1300 from its previous closing price. On the day, 1906464 shares were traded.
Ratios:
To gain a deeper understanding of AMLX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.50 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.37. For the most recent quarter (mrq), Quick Ratio is recorded 5.20 and its Current Ratio is at 5.66. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on March 18, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $32 previously.
On March 11, 2024, Robert W. Baird Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $37 to $4.
Leerink Partners Downgraded its Outperform to Market Perform on March 11, 2024, whereas the target price for the stock was revised from $27 to $4.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 05 ’24 when Klee Justin B. sold 4,135 shares for $18.73 per share. The transaction valued at 77,440 led to the insider holds 2,959,308 shares of the business.
Cohen Joshua B sold 4,135 shares of AMLX for $77,440 on Mar 05 ’24. The Co-Chief Executive Officer now owns 3,023,002 shares after completing the transaction at $18.73 per share. On Mar 05 ’24, another insider, FRATES JAMES M, who serves as the Chief Financial Officer of the company, sold 1,792 shares for $18.73 each. As a result, the insider received 33,560 and left with 134,784 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 185.05M and an Enterprise Value of -182.08M. As of this moment, Amylyx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.89. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.49 while its Price-to-Book (P/B) ratio in mrq is 0.43. Its current Enterprise Value per Revenue stands at -0.48 whereas that against EBITDA is -4.56.
Stock Price History:
Over the past 52 weeks, AMLX has reached a high of $31.77, while it has fallen to a 52-week low of $2.70. The 50-Day Moving Average of the stock is 13.4546, while the 200-Day Moving Average is calculated to be 17.4587.
Shares Statistics:
It appears that AMLX traded 2.87M shares on average per day over the past three months and 5.27M shares per day over the past ten days. A total of 67.71M shares are outstanding, with a floating share count of 47.51M. Insiders hold about 29.83% of the company’s shares, while institutions hold 89.52% stake in the company. Shares short for AMLX as of Feb 29, 2024 were 4.37M with a Short Ratio of 1.52, compared to 5.44M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.44% and a Short% of Float of 8.58%.
Earnings Estimates
As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0.32 and a low estimate of -$0.38, while EPS last year was $0.02. The consensus estimate for the next quarter is -$0.5, with high estimates of $0 and low estimates of -$1.05.
Analysts are recommending an EPS of between $0.3 and -$2.65 for the fiscal current year, implying an average EPS of -$1.35. EPS for the following year is -$0.87, with 6 analysts recommending between $1.2 and -$3.65.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $99.47M. It ranges from a high estimate of $114.32M to a low estimate of $72M. As of the current estimate, Amylyx Pharmaceuticals Inc’s year-ago sales were $71.43M, an estimated increase of 39.30% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $44.92M, a decrease of -54.30% less than the figure of $39.30% in the same quarter last year. There is a high estimate of $91.8M for the next quarter, whereas the lowest estimate is $17.25M.
A total of 7 analysts have provided revenue estimates for AMLX’s current fiscal year. The highest revenue estimate was $336M, while the lowest revenue estimate was $72.5M, resulting in an average revenue estimate of $178.8M. In the same quarter a year ago, actual revenue was $380.79M, down -53.00% from the average estimate.
